指南与共识眼底病与葡萄膜炎

近视性脉络膜新生血管:综述、指导与共识管理声明

Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.
指南 / 共识 · Ophthalmology · 2017-06-24

本文综述近视性脉络膜新生血管(CNV)的分类、病理生理与临床特征,并汇总截至2015年9月的文献管理数据以提出指导。共筛选566篇摘要,最终纳入223篇文章。共识指出高度近视患者突发中心视力丧失应转诊检查,确诊后经荧光素血管造影应尽快启动治疗,抗VEGF药物可作为一线治疗(除非禁忌),并需持续监测进展或复发。

要点

  • 高度近视患者突发中心视力丧失应转诊进一步检查。
  • 确诊近视性CNV后经荧光素血管造影应尽快治疗,抗VEGF药物可作为一线治疗(除非禁忌)。
  • 需持续监测患者以评估病情进展或复发。

核心结论

  • 高度近视患者突发中心视力丧失应转诊进一步检查。
  • 确诊近视性CNV后,经荧光素血管造影应尽快启动治疗,抗VEGF药物可作为一线治疗(除非禁忌)。
  • 需要持续监测患者以评估病情进展或复发。

研究设计与样本

  • 文献综述:2015年9月在PubMed检索所有英文文献,检索词包括「脉络膜新生血管」与「近视」或「近视性黄斑变性」或「变性近视」或「近视性黄斑病变」或「近视性视网膜病变」或「病理性近视」或「病理近视」。
  • 共筛选566篇摘要,250篇被认为相关并接受全文审查,进一步排除71篇,另补充识别44篇,最终223篇文章用于制定本综述。

主要发现

  • 病理性近视(PM)估计影响全球高达3%的人口。
  • 近视性CNV是PM最严重的并发症之一,常导致中心视力突然起病但进行性下降,若不治疗预后差。
  • 35%的近视性CNV患者在8年内对侧眼发生双侧病变。
  • 玻璃体腔注射抗血管内皮生长因子(VEGF)治疗对近视性CNV患者的管理产生了重大影响,但对该病的理解及如何最佳给药仍存在显著空白,且这些治疗的长期安全性和有效性 largely unknown。

临床怎么用

  • 高度近视患者突发中心视力丧失应转诊进一步检查(原文结论)。
  • 确诊近视性CNV后,经荧光素血管造影应尽快启动治疗,抗VEGF药物可作为一线治疗(除非禁忌)(原文结论)。
  • 需要持续监测患者以评估病情进展或复发(原文结论)。

局限性

  • 对近视性CNV的理解及如何最佳给药仍存在显著空白。
  • 抗VEGF治疗的长期安全性和有效性 largely unknown。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: The aim of this article is to review and compile available information on the classification, pathophysiology, and clinical features of myopic choroidal neovascularization (CNV); to describe the latest data on the management of this disease; and to present guidance. CLINICAL RELEVANCE: In the United States, myopia affects approximately 34 million people (2010), and similar figures have been reported in Europe. Pathologic myopia (PM), a possible consequence of myopia, is estimated to affect up to 3% of the global population. One of the most serious complications of PM is myopic CNV, which often leads to a sudden onset but progressive decline in central vision and is associated with a poor prognosis unless treated. Furthermore, 35% of patients with myopic CNV develop bilateral disease in the fellow eye within 8 years. Although intravitreal anti-vascular endothelial growth factor (VEGF) therapies have had a major impact on the management of patients with myopic CNV, there remain significant gaps in our understanding of this condition and how to best administer treatment. Additionally, the long-term safety and efficacy of these treatments are largely unknown. METHODS: We carried out a literature review (September 2015) of all English-language articles in PubMed resulting from searches of the following terms: "choroidal neovascularization" AND "myopia" OR "myopic macular degeneration" OR "degenerative myopia" OR "myopic maculopathy" OR "myopic retinopathy" OR "pathological myopia" OR "pathologic myopia." RESULTS: We screened a total of 566 abstracts, and 250 articles were deemed relevant for full publication review. We excluded a further 71, but an additional 44 articles were identified. This resulted in 223 articles being used to develop this review. CONCLUSIONS: Highly myopic patients experiencing a sudden loss of central vision should be referred for further examination. Once a diagnosis of myopic CNV has been confirmed, after fluorescein angiography, treatment initiation should be prompt and anti-VEGF agents considered as first-line therapy, unless contraindicated. Continued monitoring of patients is required to assess any progression or recurrence of the condition.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Cheung CMG, Arnold JJ, Holz FG, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017. PMID: 28655539. doi:10.1016/j.ophtha.2017.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。